Viyash Scientific Q4 FY26 Revenue Up 19.1% to ₹9,200 Million, EBITDA Up 63.8%
Viyash Scientific reported Q4 FY26 revenue of ₹9,200 million, a 19.1% increase, and EBITDA of ₹2,001 million, up 63.8%. PAT for Q4 FY26 was ₹664 million, up 306%. FY26 revenue reached ₹34,203 million, up 13.8%, with EBITDA at ₹7,025 million, up 59.6%. Dr. Hari Babu Bodepudi noted the successful integration of operations. An earnings call is scheduled for May 20, 2026, at 16:00 IST.
The announcement showcases a substantial increase in revenue and profit, indicating a positive outlook for the company. The management's commentary further reinforces this positive impact.
The announcement highlights strong financial performance with significant growth in revenue, EBITDA, and PAT, along with positive comments from the management regarding the company's future prospects.
Viyash Scientific Limited (formerly known as Sequent Scientific Limited) announced its financial results for the quarter and year ended March 31, 2026. The company reported its strongest quarter in history, with EBITDA surpassing ₹200 crore. FY26 was a transformative year, marked by the successful integration of facilities, operations, and corporate functions into one unified platform. This integration has strengthened execution, improved operating leverage, and enhanced resilience amidst geopolitical and maritime disruptions. The company continues to navigate these challenges through disciplined asset utilization, cost controls, and agile pricing strategies. Looking ahead to FY27, Viyash Scientific is excited about its product pipeline and growth roadmap and is actively evaluating selective inorganic opportunities to further strengthen its platform and create long-term value, supported by a significantly deleveraged balance sheet. Revenue for Q4 FY26 stood at ₹9,200 million, up by 19.1%, with EBITDA at ₹2,001 million, up 63.8%. The PAT for Q4 FY26 was ₹664 million, up by 306%. For FY26, revenue was ₹34,203 million, up by 13.8%, with EBITDA at ₹7,025 million, up 59.6%. The PAT for FY26 was ₹2,246 million, up by 1324%. Net Debt / EBITDA* stood at 0.2x. Dr. Hari Babu Bodepudi, Managing Director and Group CEO, commented that Q4 was the strongest quarter in the Company’s history, with merger synergies beginning to reflect meaningfully in financial performance. The company will conduct an earnings call at 16:00 IST on May 20, 2026, to discuss the company’s performance and answer questions from participants.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.